Hypercholesterolemia - Pipeline Review, H2 2016
"Hypercholesterolemia
- Pipeline Review, H2 2016"
The Report covers current Market Trends, Worldwide Analysis, Global
Forecast, Review, Share, Size, Growth, Effect.
Description-
Global
Markets Direct's latest Pharmaceutical and Healthcare disease
pipeline guide Hypercholesterolemia Pipeline Review, H2 2016,
provides an overview of the Hypercholesterolemia (Metabolic
Disorders) pipeline landscape.
Hypercholesterolemia
arises due to high levels of cholesterol in the blood. These abnormal
levels may lead to various diseases especially cardiovascular
diseases. Cholesterol deposit in the arteries and may cause the
narrowing of blood vessels hence restricting the blood flow. The
predisposing factors for hypercholesterolemia include various
diseases such as diabetes mellitus, renal diseases, obesity etc. The
other factors involved are heredity, certain drugs, sedentary
lifestyle, smoking, alcoholism, stress and high fat diet. The
symptoms for hypercholesterolemia include blocked arteries, leg pain,
chest pain and cholesterol deposits. The disease can be controlled by
lifestyle changes, dietary changes, and medications.
Report
Highlights
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Hypercholesterolemia Pipeline Review, H2 2016, provides comprehensive
information on the therapeutics under development for
Hypercholesterolemia (Metabolic Disorders), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
The
Hypercholesterolemia (Metabolic Disorders) pipeline guide also
reviews of key players involved in therapeutic development for
Hypercholesterolemia and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery
and Unknown stages are 11, 13, 5, 1, 17, 8 and 1 respectively.
Similarly, the Universities portfolio in Preclinical and Discovery
stages comprises 7 and 2 molecules,
respectively.Hypercholesterolemia.
Scope
-
The pipeline guide provides a snapshot of the global therapeutic
landscape of Hypercholesterolemia (Metabolic Disorders).
-
The pipeline guide reviews pipeline therapeutics for
Hypercholesterolemia (Metabolic Disorders) by companies and
universities/research institutes based on information derived from
company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages
of development ranging from pre-registration till discovery and
undisclosed stages.
-
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive
licensing and collaboration details, R&D brief, MoA & other
developmental activities.
Reasons
to buy
-
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive
advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Hypercholesterolemia (Metabolic Disorders).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of
leading companies.
-
Plan mergers and acquisitions meritoriously by identifying key
players and its most promising pipeline therapeutics.
Comments
Post a Comment